New Trends in the Detection of Gynecological Precancerous Lesions and Early-Stage Cancers

New Trends in the Detection of Gynecological Precancerous Lesions and Early-Stage Cancers

The prevention and early diagnostics of precancerous stages hold a crucial position   in contemporary oncology. 

The mutational topography of cancer is induced through a combination of environmental and endogenous stresses that leads to base substitutions, insertions, deletions, and chromosomal rearrangements. These alterations not only cause the disease but can also serve to detect cancer in its early stages. 

Liquid biopsy strategies are promising since they are minimally invasive and are primarily established on the characterization of circulating tumor DNA, circulating tumor cells, and circulating extracellular vesicles as sources of proteomic and genetic information reflecting alterations in transformed cells.

Prevention strategies involve vaccinations and well-organized screening programs, including cytology with an HPV testing triage that enables early diagnostics by expert colposcopies and biopsies, followed in most cases by early treatment in the precancerous stages of the disease. This combination has caused a dramatic decline in invasive cervical cancer (CC) incidence and mortality. Following all these conditions, cervical cancer could be made a preventable disease. However, endometrial and ovarian cancers are diagnosed only after the appearance of symptoms. In these tumors, diagnostics are restricted by the relatively poor accessibility of the uterus and ovaries for sampling. Like in endometrial cancer (EC), transvaginal ultrasound could not be concluded as a promising screening method. Thus the focus remains particularly on women at a higher risk, i.e., characterized by obesity, diabetes, hypertension, or Lynch syndrome. The disease is diagnosed on the onset of the first symptoms, usually bleeding. When curettage is performed instantly and the disease is established, operative treatments show good results. However, for Epithelial Ovarian Cancer (EOC), neither an effective screening method nor the ability to accurately define a high-risk group is established, indicating that > 75% of women are diagnosed with an advanced stage disease. 

Surgical improvements followed by systemic and biologic targeted therapies remains useful for existing patients, but the discovery and implementation of new diagnostic and/or prognostic biomarkers, especially those detectable in liquid biopsies, will aid in early detection and improved patient outcomes.

SOURCE- Cancers. Cancers. 2021; 13(24):6339.

IJCP Editorial Team

Comprising seasoned professionals and experts from the medical field, the IJCP editorial team is dedicated to delivering timely and accurate content and thriving to provide attention-grabbing information for the readers. What sets them apart are their diverse expertise, spanning academia, research, and clinical practice, and their dedication to upholding the highest standards of quality and integrity. With a wealth of experience and a commitment to excellence, the IJCP editorial team strives to provide valuable perspectives, the latest trends, and in-depth analyses across various medical domains, all in a way that keeps you interested and engaged.

 More FAQs by IJCP Editorial Team


Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks